Details of the Drug Pharmacogenomic Perturbation Atlas

Pefloxacin Drug Info

Abactal; Labocton; PERFLOXACIN; PFLX; Peflacine; Pefloxacine; Pefloxacino; Pefloxacinum; Pefloxacin methanesulfonate; Silver Pefloxacin; AM-725; EU-5306; Pefloxacin [INN-French]; Pefloxacino [INN-Spanish]; Pefloxacinum [INN-Latin]; Pefloxacin (USAN/INN); Pefloxacin [USAN:BAN:INN]; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo

Therapeutic Class

Antiinfective Agents

Cross-matching ID

PubChem CID

51081

ChEBI ID

CHEMBL267648

CAS Number

CAS 70458-92-3

TTD Drug ID

D04NXQ

General Information of Drug (ID: DM49IGF)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Amino sugar and nucleotide sugar metabolism	-1.64	4.76e-2	38/48 (79.17%)	NANS;PGM3;HEXB;...
Natural killer cell mediated cytotoxicity	-1.64	4.97e-2	99/131 (75.57%)	PLCG1;RAC2;CD247;...
Arrhythmogenic right ventricular cardiomyopathy	-1.68	4.50e-2	70/77 (90.91%)	SGCG;ITGA3;TCF7L2;...
Focal adhesion	-1.71	3.46e-2	180/201 (89.55%)	COL9A2;ITGA7;MET;...
Thyroid hormone signaling pathway	-1.71	3.43e-2	112/121 (92.56%)	KRAS;TSC2;GATA4;...
Porphyrin and chlorophyll metabolism	-1.73	2.54e-2	23/43 (53.49%)	UGT2B15;GUSB;UGT2A3;...
Collecting duct acid secretion	-1.74	2.64e-2	22/27 (81.48%)	TCIRG1;ATP6V0A1;ATP4B;...
Cholesterol metabolism	-1.77	2.09e-2	44/50 (88%)	SOAT2;LRP1;LRPAP1;...
Ovarian steroidogenesis	-1.79	1.80e-2	41/51 (80.39%)	CGA;HSD3B2;HSD3B1;...
Hypertrophic cardiomyopathy	-1.81	1.98e-2	81/90 (90%)	IGF1;ITGB3;MYL3;...
Phagosome	-1.81	1.90e-2	118/152 (77.63%)	HLA-DRB1;CYBB;HLA-G;...
ECM-receptor interaction	-1.85	8.24e-3	80/88 (90.91%)	TNXB;SDC4;SPP1;...
Lysosome	-1.87	7.53e-3	115/128 (89.84%)	CD68;GAA;TCIRG1;...
Dilated cardiomyopathy	-1.88	6.59e-3	86/96 (89.58%)	IGF1;ITGB3;MYL3;...
Galactose metabolism	-1.94	7.91e-3	26/31 (83.87%)	HK2;UGP2;GALT;...
Fat digestion and absorption	-1.95	6.59e-3	35/43 (81.4%)	LIPF;APOA4;AGPAT2;...
Steroid hormone biosynthesis	-1.96	8.79e-3	43/61 (70.49%)	CYP11B1;UGT2B15;DHRS11;...
Protein processing in endoplasmic reticulum	-1.97	6.59e-3	127/171 (74.27%)	RPN1;BAK1;STT3A;...
Protein digestion and absorption	-2.06	1.32e-2	78/103 (75.73%)	SLC36A1;COL5A1;COL17A1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H

Prostate

Prostate carcinoma

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H